Macrogol 3350 Plus Electrolytes
Recommended · restricted GastroenterologyRestrictedSecond-line line
Extension of listing for chronic constipation or faecal impaction not adequately controlled with first-line interventions such as bulk-forming agents, and listing of half-strength formulation for the same indication.
1
Submissions
1 resub
2007–07
On the record
—
ICER range
Not modelled
Cost basis
Access path
- Nov 2007Recommended · restricted
vs lactulose, placebo, ispaghula husk
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
No economic evaluation generated by the sponsor was presented; submission cited results of five published pharmacoeconomic studies but no ICER was calculated or stated in the PSD.
Decision context
PopulationAdults and children with chronic constipation or faecal impaction not adequately controlled with first-line interventions such as bulk-forming agents; half-strength formulation for use in adults and children aged 2 years and older.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2007 | Recommended · restricted | lactulose, placebo, ispaghula husk | — | RCT · Complete defecations per week |